Estradiol Cypionate

Summary

Estradiol Cypionate (CHEMBL1200973) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Clinical trials: 7
• Chemistry: 396.6 Da · C26H36O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200973
Name	Estradiol Cypionate
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	9403
Molecular formula	C26H36O3
Molecular weight	396.6
InChIKey	UOACKFBJUYNSLK-XRKIENNPSA-N

SMILES: C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2OC(=O)CCC4CCCC4)CCC5=C3C=CC(=C5)O

IUPAC name: [(8R,9S,13S,14S,17S)-3-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] 3-cyclopentylpropanoate

Also known as: Depo, Depo-estradiol, Estradiol cipionate, Estradiol cypionate, Estradiol cypionate component of lunelle, NSC-3354, SID46500620, ESTRADIOL CYPIONATE, SID69855, SID144205884, SID144203554, SID170464789

Patent coverage: 1,133 distinct patent families (4,089 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 4,075 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 7 (assay-derived). Sample: Androgen receptor, Estrogen receptor, Progesterone receptor, Prostaglandin G/H synthase 1, cGMP-inhibited 3’,5’-cyclic phosphodiesterase 3A, 3’,5’-cyclic-AMP phosphodiesterase 4A, Adenosine receptor A3.

Bioactivity

ChEMBL activities: 5 potent at pChembl ≥ 5 of 7 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
ESR1	6.42	AC50	378.9	nM	CHEMBL_ACT_25138573
AR	6.13	AC50	741.7	nM	CHEMBL_ACT_25203073
PGR	5.78	AC50	1649	nM	CHEMBL_ACT_25204006
PTGS1	5.36	AC50	4375	nM	CHEMBL_ACT_25204939
ADORA3	5	AC50	9985	nM	CHEMBL_ACT_25198489

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 7.

Phase distribution

Phase	Trials
PHASE2	3
Not specified	2
PHASE3	1
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03511625	PHASE3	UNKNOWN	The Effects of Acthar on Synovial Inflammation in Rheumatoid Arthritis
NCT04693312	PHASE2/PHASE3	COMPLETED	Injection of Dorsal Scapular n at Different Levels, Dose it Make Difference?
NCT00807625	PHASE2	COMPLETED	Impact of Different Contraceptives on the Immune System of HIV Infected Women in Zambia
NCT04865029	PHASE2	TERMINATED	Estradiol and Progesterone in Hospitalized COVID-19 Patients
NCT06057012	PHASE2	COMPLETED	A Study of BRII-296 in Adults With Severe Postpartum Depression (PPD)
NCT02367560	Not specified	UNKNOWN	Calcific Tendinitis: Comparing Minimally Invasive Modalities
NCT05971004	Not specified	COMPLETED	Effectiveness of Hydrolyzed Collagen Peptide Injection for the Treatment of Collateral Ligament Pain

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).